Shivem B. Shah

Columbia University Irving Medical Center

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity”.

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity

Cancer Cell(2023)10.1016/j.ccell.2023.05.014

N/A

1.8DataRank · unranked

96 citations

Johannes C. Melms, Meri Rogava, Chris J. Frangieh, Joanna Poźniak, Shivem B. Shah +28 more

Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas

Nature Materials(2023)10.1038/s41563-023-01495-3

N/A

1.4DataRank · unranked

48 citations

Christopher R. Carlson, Kristine Lai, Zhe Zhong, Grazia Marsico, Katherine M. Lee +25 more

Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens

Nature Biotechnology(2024)10.1038/s41587-024-02235-x

N/A

0.896DataRank · unranked

36 citations

Parin Shah, Neeharika Kothapalli, Shivem B. Shah, Gergő Nikolényi, D. Zack Brodtman +12 more

Dissecting the treatment-naive ecosystem of human melanoma brain metastasis

Cell(2022)10.1016/j.cell.2022.06.007

N/A

0.807DataRank · unranked

216 citations

Johannes C. Melms, Amit Dipak Amin, Yiping Wang, Lindsay Caprio, Alcida Karz +54 more

The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.21.485049

N/A

0.360DataRank · unranked

10 citations

Johannes C. Melms, Meri Rogava, Chris J. Frangieh, Shivem B. Shah, Zachary Walsh +21 more

Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes

Blood Advances(2020)10.1182/bloodadvances.2020002580

N/A

0DataRank · unranked

53 citations

Regan E. Stephenson, Raymond Reynolds, Shivem B. Shah, Rishi Puri, Scott D. Butler +13 more